Protecting the Warfighter’s health and readiness, now and into the future [Image 2 of 4]

FORT DETRICK, MD, UNITED STATES

03.16.2023

Courtesy Photo

U.S. Army Medical Materiel Development Activity (USAMMDA)

Dr. Clifford Snyder, product manager for the Warfighter Protection and Acute Care Project Management Office, U.S. Army Medical Materiel Development Activity, briefs the importance of the adenovirus vaccine during the U.S. Army Medical Research and Materiel Command VIP Medical Lanes event, 2017. The adenovirus vaccine is the only FDA-approved vaccine to prevent febrile acute respiratory disease caused by adenovirus. In 2022, developers with WPAC PMO established a contract with the manufacturer of the adenovirus vaccine to modernize their manufacturing capability and improve the supply chain. This effort reduces the risk of disruptions from a sole supplier and ensures the product is readily available at U.S. military Initial Entry Training sites to help maintain operational readiness. (Official U.S. Army Photo by Erin Bolling/Released)

• Date Taken: 03.16.2023
• Date Posted: 03.16.2023 14:52
• Photo ID: 7685067
• VIRIN: 230316-A-A4491-001
• Resolution: 5308x4000
• Size: 2.98 MB
• Location: FORT DETRICK, MD, US